Regeneron Pharmaceuticals, Inc. Raises 2012 Eylea Sales Forecast

Regeneron Pharmaceuticals Inc (REGN.O) significantly raised its 2012 sales forecast for its key eye drug Eylea, suggesting fast adoption of the recently approved drug, sending its shares to a lifetime high. The company, which has a market capitalization of about $10 billion, now expects Eylea net sales of $250 million to $300 million in the United States in 2012. It had earlier forecast net sales of $140 million to $160 million for the drug, which received U.S. regulatory approval in November to treat a common cause of blindness in the elderly.

Back to news